Cardiovascular Efficacy of Lipid-Lowering Drug Targets Is Not Entirely Explained by Apolipoprotein B Reduction: Mendelian Randomization Evidence.
Dipender GillBenjamin WoolfLoukas ZagkosHéléne Toinét CronjéJoanna TzoulakiPublished in: Circulation. Genomic and precision medicine (2023)